ReviewActa neuropathologica communications2025
Endothelial transdifferentiation of glioma stem cells: a literature review.
Review in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The WYZ-1 mouse glioblastoma stem cell model: A novel preclinical tool for tumor and therapy studies.Cancer letters · 2026Article
- Integrating Molecular Pathology, Tumor Microenvironment, and Novel Therapies to Overcome Resistance in Glioblastoma.Journal of molecular neuroscience : MN · 2026Review
- Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.Brain sciences · 2026Review
- Next-generation platelet concentrate: Alb-PRF outperformed PRP and H-PRF in promoting endothelial function and wound healing.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelial transdifferentiation represents a multifaceted process wherein glioma stem cells (GSCs) gradually adopt endothelial characteristics, marked by the expression of endothelial markers (CD31, CD34) and functional traits, while concurrently relinquishing their stem-like properties. This phenomenon is heterogenous in glioblastoma (GBM) samples, but holds importance in terms of prognosis. Typically occurring within hypoxic environments, particularly in perinecrotic regions, endothelial transdifferentiation is influenced by the secretome of neighboring cells, which orchestrates the activation of various signaling pathways including Notch during endothelial lineage commitment, PI3K/AKT, Wnt/β-catenin and epithelial-mesenchymal transition (EMT) during both commitment and maturation. Initially, GSCs organize into vascular-like channels resembling vasculogenic mimicry and express CD144; however, this signature diminishes as endothelial maturation progresses. GSC-derived endothelial cells (ECs) eventually integrate with normal ECs from the tumor periphery, yielding a mosaic pattern. Endothelial transdifferentiation plays a role in response to standard treatments such as temozolomide chemotherapy and radiotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.